-
Innovation Ranking
NewInnovation Ranking – Rongsheng Petrochemical Co Ltd
Rongsheng Petrochemical Co Ltd (Rongsheng), a subsidiary of Zhejiang Rongsheng Holding Group Co Ltd is a chemical company that produces and distributes pure terephthalic acid (PTA), polyester fiber, and chemical products. The company’s products include synthetic fibers and films, synthetic resins, synthetic raw material, olefin, and special chemical products, aromatics and phenols, intermediate and chemical raw materials, and oil products. It distributes its products in China, the US, France, South Korea, Chile, Vietnam, Hong Kong, Japan, Greece, and other countries....
-
Company Insights
Innovation and Patenting activity of Rongsheng Petrochemical Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Rongsheng Petrochemical Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Sector Analysis
NewPurified Terephthalic Acid (PTA) Industry Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants to 2028
Purified Terephthalic Acid (PTA) Capacity & Capital Expenditure (Capex) Overview The Purified Terephthalic Acid (PTA) capacity was 121.23 million tonnes per annum (mtpa) in 2023 and will increase at an AAGR of more than 5% from 2023 to 2028. In 2023, Iran, Saudi Arabia, and Turkey were the leading countries in the Middle East accounting for the total PTA capacity in the region. Large-scale production of polyester fiber in these regions, using PTA, drives its increasing consumption. This fiber finds...
-
Product Insights
Rabies – Drugs In Development, 2023
Global Markets Direct’s, ‘Rabies - Drugs In Development, 2023’, provides an overview of the Rabies pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rabies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Primary Immune Deficiency (PID) – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Immune Deficiency (PID) - Drugs In Development, 2023’, provides an overview of the Primary Immune Deficiency (PID) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Sector Analysis
Acrylonitrile Industry Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants to 2028
Acrylonitrile Industry Capacity & Capital Expenditure (Capex) Overview The acrylonitrile industry capacity was 9.55 million tonnes per annum (mtpa) in 2023. China, the US, South Korea, Japan, and Taiwan were the key countries accounting for most of the acrylonitrile capacity in 2023. The acrylonitrile industry capacity will garner an AAGR of more than 4% from 2023 to 2028. In terms of global Capex spending non acrylonitrile industry planned and announced projects, Asia will account for the largest regional share with...
-
Product Insights
Thrombocytopenia – Drugs In Development, 2023
Global Markets Direct’s, ‘Thrombocytopenia - Drugs In Development, 2023’, provides an overview of the Thrombocytopenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thrombocytopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Cytomegalovirus (HHV-5) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Cytomegalovirus (HHV-5) Infections - Drugs In Development, 2023’, provides an overview of the Cytomegalovirus (HHV-5) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DF-9001 in Hypopharyngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DF-9001 in Hypopharyngeal Cancer Drug Details: DF-9001 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Immune Globulin (Human) in Thrombocytopenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Immune Globulin (Human) in Thrombocytopenia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Immune Globulin (Human) in Thrombocytopenia Drug Details:Immune globulin (IVIG) is under development...